Skip to main content
SpringerLink
Log in

Differentielle Ansätze zur pharmakologischen Rezidivprophylaxe schizophrener Störungen

  • Conference paper
Schizophrenie

  • 181 Accesses

Zusammenfassung

Die pharmakologische Langzeitbehandlung mit dem Ziel der Prophylaxe schizophrener Reexazerbationen gehört zu den bestgesicherten Behandlungsformen psychischer Erkrankungen. Entscheidendenden Beitrag dazu lieferte die Entwicklung und systematische Evaluation verschiedener Behandlungsstrategien mit Neuroleptika. Durch eine konsequente Weiterentwicklung sind nicht nur Substanzen mit optimiertem Wirkungs-/Nebenwirkungsprofil entstanden, sondern die Forschung auf diesem Gebiet hat auch zur Vertiefung ätiopathogenetischer Kenntnisse geführt. Ausgehend von dem Vulnerabilitäts-Stress-Coping-(VSC-)Modell sind unter Einbeziehung psycho-sozialer und rehabilitativer Ansätze umfassende Therapiestrategien entstanden, die die sekundäre und tertiäre Prävention deutlich verbessert haben. Mittlerweile liegen zumindest teilweise empirisch validierte Konzepte zu Entstehung und Verlauf vor, die einen Zuschnitt der Behandlung auf individuelle Erfordernisse ermöglichen. Im Sinne einer Evidenz-basierten Medizin hat diese Entwicklung zur Formulierung von Therapieleitlinien geführt, die die Umsetzung des wissenschaftlichen Kenntnisstandes in die Praxis und die Behandlungsplanung fördern sollen (Gaebel, 1999; Mellman et al, 2001). Im Folgenden werden die wesentlichen differentiellen Ansätze zur neuroleptischen Rezidivprophylaxe schizo phrener Psychosen dargestellt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Psychiatrie Association (1997) Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 154 (4) [Suppl]

    Google Scholar 

  • Birchwood M, Spencer E (2001) Early intervention in psychotic relapse. Clin Psychol Rev 21 (8): 1211–1226

    Article  PubMed  CAS  Google Scholar 

  • Brown GW, Bone M, Dalison B, Wing JK (1966) Schizophrenia and social care. Oxford University Press, London

    Google Scholar 

  • Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, Buchanan RW (1990) Continuous versus targeted medication in schizophrenie outpatients: outcome results. Am J Psychiatry 147: 1138–1148

    PubMed  Google Scholar 

  • Carpenter WT, Buchanan RW, Kirkpatrick B, Breier AF (1999) Diazepam treatment of early signs of exacerbation in schizophrenia. Am J Psychiatry 156: 299–303

    PubMed  Google Scholar 

  • Cheung HK (1981) Schizophrenics fully remitted on neuroleptics for three-five years: to stop or continue drugs? Br J Psychiatry 138: 490–494

    Article  PubMed  CAS  Google Scholar 

  • Chiles JA, Sterchi D, Hyde T, Herz MI (1989) Intermittent medieation for schizophrenie outpatients: who is eligible? Schizophr Bull 15: 117–121

    PubMed  CAS  Google Scholar 

  • Csernansky JG, Bellows EP, Barnes DE, Lombrozo L (1990) Sensitization versus tolerance to the dopamine turnover-e1evating effects ofhaloperidol: the effect of regular/intermittent dosing. Psychopharmacol 101: 519–524

    Article  CAS  Google Scholar 

  • Csernansky JG, Mahmoud R, Brenner R (2002) Acomparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16–22

    Article  PubMed  CAS  Google Scholar 

  • Davis J, Schaffer C, Killian G, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6: 70–87

    PubMed  CAS  Google Scholar 

  • Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Hrsg) (1998) Behandlungsleitlinie Schizophrenie

    Google Scholar 

  • Emsley R (1999) Risperidone in the treatment of first-episode psychotie patients: a double-blind multieenter study. Schizophr Bull 25 (4): 721–729

    PubMed  CAS  Google Scholar 

  • Gaebel W (1999) Internationale Leitlinien der Schizophreniebehandlung. In: Möller H-J, Müller N (Hrsg) Atypische Neuroleptika. Steinkopff, Darmstadt, S 79–91

    Google Scholar 

  • Gaebel W (1996) Medikamentöse Frühintervention in der Rückfallprophylaxe: Grundlagen, Indikation und Durchführung. In: Böker W, Brenner HD (Hrsg) Integrative Therapie der Schizophrenie. Huber, Bern, S 249–263

    Google Scholar 

  • Gaebel W, Awad AG (1994) Prediction of neuroleptic treatment outcome in schizophrenia concepts and methods. Springer, Wien New York, pp 15–26

    Google Scholar 

  • Gaebel W, Friek U, Köpcke W, Linden M, Müller P, Müller-Spahn F, Pietzker A, Tegeler J (1993) Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse. Br J Psychiatry 163 [Suppl 21]: 8–12

    Google Scholar 

  • Gaebel W, Jänner M, Frommann N, Pietzcker A, Köpcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J (2000) Prodromal states in schizophrenia. Compr Psychiatry 41 [Suppl 1]: 76–85

    Article  PubMed  CAS  Google Scholar 

  • Gaebel W, Jänner M, Frommann N, Pietzcker A, Köpcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J (2002) First vs. multiple episode schizophrenia: two-year outcome ofintermittent and maintenance medieation strategies. Schizophr Res 53: 145–159

    Article  PubMed  Google Scholar 

  • Geddes J (2002) Prevention of relapse in schizophrenia. N Engl J Med 346: 56–58

    Article  PubMed  Google Scholar 

  • Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systemic overview and meta-regression analysis. BMJ 32: 1371–1376

    Article  Google Scholar 

  • Glazer WM, Kane JM (1992) Depot neuroleptie therapy: an underutilized treatment option? J Clin Psychiatry 53: 426–433

    PubMed  CAS  Google Scholar 

  • Glenthoj B, Hemmingsen R, Allerup P, Bolwig TG (1990) Intermittent vs. continuous neuroleptic treatment in a rat model. Eur J Pharmacol 190: 275–286

    Article  PubMed  CAS  Google Scholar 

  • Green MF, Marder RS, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J (2002) The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 51: 972–978

    Article  PubMed  CAS  Google Scholar 

  • Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G (1994) One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 151: 1409–1416

    PubMed  CAS  Google Scholar 

  • Herz MI, Glazer W, Mostert M, Sheard MA, Szymanski HV, Hafez HM, Vana J (1991) Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 48: 333–339

    PubMed  CAS  Google Scholar 

  • Herz M, Melville C (1980) Relapse in schizophrenia. Am J Psychiatry 137: 801–812

    PubMed  CAS  Google Scholar 

  • Herz MI, Lamberti SJ (1995) Prodromal symptoms and relapse prevention in schizophrenia. Schizophr Bull 21 (4): 541–551

    PubMed  CAS  Google Scholar 

  • Herz MI, Lamberti JS, Mintz J, Scott R, O’Dell SP, McCartan L, Nix G (2000) A program for relapse prevention in schizophrenia. Arch Gen Psychiatry 57: 277–283

    Article  PubMed  CAS  Google Scholar 

  • Hogarty GE, Goldberg SC (1973) Drugs and sociotherapy in the aftercare of schizophrenie patients: one-year relapse rates. Arch Gen Psychiatry 28: 54–64

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Goldberg SC, Ulrich RF (1974) Drugs and sociotherapy in the aftercare of schizophrenie patients, II: two-year relapse rates. Arch Gen Psychiatry 31: 603–608

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Ulrieh RF (1998) The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions to psychsocial treatment. J Psychiatr Res 32: 243–250

    Article  PubMed  CAS  Google Scholar 

  • Hogarty GE, Ulrich RF, Mussare F, Arishgueta N (1976) Drug discontinuation among long term, successfully maintained schizophrenie outpatients. Dis Nerv Syst 37: 494–500

    PubMed  CAS  Google Scholar 

  • Hogarty GE, Schooler NR, Ulrieh RF, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenie patients: relapse analysis of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 36: 1283–1294

    PubMed  CAS  Google Scholar 

  • Jeste DV, Potkin SG, Sinha S, Feder SL and Wyatt RJ (1979) Tardive dyskinesia — reversible and persistent. Arch Gen Psychiatry 36: 585–590

    PubMed  CAS  Google Scholar 

  • Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L (1990) Trial of brief intermittent neuroleptie prophylaxis for selected schizophrenie outpatients: clinical and social outcome at two years. BMJ 301: 837–842

    Article  PubMed  CAS  Google Scholar 

  • Kahn RS, Fleischhacker W, Keet R et al (2001) The European First Episode Schizophrenia Trial (EUFEST). Compariason of outcome in first episode schizophrenia with different antipsychotic drug regimes (unpublished manuscript)

    Google Scholar 

  • Kane JM, Marder SR (1993) Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19: 287–302

    PubMed  CAS  Google Scholar 

  • Lehmann AF (1996) Evaluating outcomes of treatments for persons with psychotic disorders. J Clin Psychiatry 57 [Suppl 11]: 61–67

    Google Scholar 

  • Leucht S, Barnes T, Kissling W, Engel R, Kane J (2003) A meta-analys is on relapse prevention in schizophrenia with new antipsychotics. Am J Psychiatry (submitted)

    Google Scholar 

  • Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35: 51–68

    Article  PubMed  CAS  Google Scholar 

  • Lieberman JA, Sheitman BB, Kinon BJ (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacol 17: 205–229

    Article  CAS  Google Scholar 

  • Marder RS, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM, Lieberman J, Schooler NR (2002) The mount sinai conference on the pharmacotherapy of schizophrenia. Schizophr Bull 28: 5–16

    PubMed  Google Scholar 

  • Marder SR, Hubbard JW, Van Putten T, Midha KK (1989) Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacol 98: 433–439

    Article  CAS  Google Scholar 

  • McEvoy J, Scheifler P, Frances A (1999) The expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry 60 [Suppl 11]

    Google Scholar 

  • Mellman TA, Miller AL, Weissman EM, Crismon ML, Essock SM, Marder RS (2001) Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms. Psychiatr Serv 52: 619–625

    Article  PubMed  CAS  Google Scholar 

  • National Institute for Clinical Excellence (NICE) (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance 43 (www.nice.org.uk)

  • Nuechterlein KH, Dawson ME (1984) A heuristic vulnerability/stress model of schizophrenie episodes. Schizophr Bull 10: 300–312

    PubMed  CAS  Google Scholar 

  • Pietzcker A, Gaebel W, Köpcke W, Linden M, Müller P, Müller-Spahn F, Tegeler J (1993) lntermittent versus maintenance neuroleptic long-term treatment in schizophrenia: 2-year results of a German multicenter study. J Psychiatr Res 27: 321–339

    Article  Google Scholar 

  • Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefseon G (1999) Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 156: 79–87

    PubMed  CAS  Google Scholar 

  • Stephens J (1978) Long-term prognosis and follow-up in schizophrenia. Schizophr Bull 4: 25–47

    PubMed  CAS  Google Scholar 

  • Watt DC, Katz K, Shepherd M (1983) The natural history of schizophrenia: a 5-year prospective follow-up of a representative sampie of schizophrenics by means of standardized clinical and social assessment. Psychol Med 13: 663–670

    Article  PubMed  CAS  Google Scholar 

  • Zubin J, Spring B (1977) Vulnerability: a new view of schizophrenia. J Abnormal Psychol 86: 103–126

    Article  CAS  Google Scholar 

Download references

Authors
  1. W. Gaebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Riesbeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinik der LMU München, München, Deutschland

    Hans-Jürgen Möller (Direktor der Psychiatrischen) (Direktor der Psychiatrischen)

  2. Klinik und Poliklinik für Psychiatrie und Psychotherapie, München, Deutschland

    Hans-Jürgen Möller (Direktor der Psychiatrischen) & Norbert Müller (Direktor der Psychiatrischen) & 

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag/Wien

About this paper

Cite this paper

Gaebel, W., Riesbeck, M. (2004). Differentielle Ansätze zur pharmakologischen Rezidivprophylaxe schizophrener Störungen. In: Möller, HJ., Müller, N. (eds) Schizophrenie. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0623-5_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-0623-5_19

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-40482-9

  • Online ISBN: 978-3-7091-0623-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation